Onyx CEO to retire

Hollings C. Renton, CEO of Onyx Pharmaceuticals, announced plans to retire next year. He will remain chairman of the board of directors. The company has initiated a search for his successor. Onyx has promoted Laura A. Brege to the newly-created position of executive vice president and CEO and Randy A. Kelley to senior vice president of sales and marketing. Onyx, together with Bayer, developed Nexavar, an approved live cancer therapy that made waves at this year's ASCO conference.

- see this release from Onyx

Related Articles:
Bayer, Onyx seek new Nexavar approval. Report
Bayer, Onyx tout Nexavar data. Report
Bayer, Onyx announce disappointing Nexavar results. Report

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.